Compare Fidelity National Information Servcs Inc (FIS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Viatris Inc — how do they compare? Fidelity National Information Servcs Inc trades at $34 (market cap $17.71B), while Viatris Inc trades at $17.7 (market cap $20.03B). The key difference: Fidelity National Information Servcs Inc and Viatris Inc are close in size by market cap, and Fidelity National Information Servcs Inc pays the higher dividend (5.13%). Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Viatris Inc for 57 Days on average.
| FIS | VTRS | |
|---|---|---|
Market Cap | $17.71B | $20.03B |
Volume | 9,047,825 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $68.57 | $18.27 |
52-Week Low | $32.44 | $9.74 |
Typical Hold Time | 88 Days | 57 Days |
Enterprise Value | $38.22B | $32.15B |
Dividend Yield | 5.13% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.19, up 1.09% with bearish technical signals but strong fundamentals including a low P/E of 5.27 and net income margin of 27.65%. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss. The company demonstrates business momentum with multiple core banking wins and product launches, including embedded banking platform and cloud modernization initiatives announced in September 2026.
FIS presents a compelling value opportunity with attractive valuation metrics and improving profitability, though technical indicators suggest near-term pressure. The 37% upside to consensus price target of $47.15 and strong analyst support (57% buy ratings) indicate Wall Street optimism, balanced by debt concerns and competitive fintech landscape requiring careful monitoring.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
